EBPIT
DEAD

Serial Number

88813289

Owner

Angany Inc.

Attorney

Peter Kunin

Filing Date

Feb 27, 2020

Add to watchlist:

No watchlists yet
View on USPTO

EBPIT Trademark

Serial Number: 88813289

EBPIT is a trademark filed by Angany Inc. on February 27, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Angany Inc. (3 trademarks)

873 Rue Saint-Jean, suite 200
Quebec (Quebec) G1R1R2 , CA

Entity Type: 03

Trademark Details

Filing Date

February 27, 2020

Registration Date

Not Registered

Goods & Services

Protein arrays for medical diagnosis purposes; Protein arrays for therapeutic use for treating cancer, allergies, autoimmune disease, infection disease, and inflammatory disease; biopharmaceuticals for treatment of cancer, allergies, autoimmune disease, infection disease

Development of pharmaceutical preparations and medicines; pharmaceutical research and development; software as a service (SAAS) services featuring artificial intelligence software for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining in the field of vaccinal pharmacologic treatment and allergy medications; platform as a service (PAAS) services featuring artificial intelligence software platforms for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining for use in the field of vaccinal pharmacologic treatment and allergy medications

Chemicals for scientific, laboratory and medical research; chemicals for use in the manufacture of pharmaceuticals; biochemicals, namely, antibodies for scientific, laboratory and medical research; proteins for immunoassay for detection, for diagnostic purposes, for therapeutic purposes, and for treatment of cancer, allergies, autoimmune disease, infection diseases

Medical services, namely, vaccinal pharmacologic treatment of autoimmune diseases such as psoriasis, Crohn's disease, rheumatoid arthritis, cancer, infectious diseases and allergies; health care services, namely, desensitization treatments for allergy; medical services, namely, immunotherapy in the fields of cancer, autoimmune, infectious disease and orphan diseases conditions in humans and veterinary applications; medical treatment of allergies, cancer, and auto-immune diseases destined to generate, in response to its administration in patients, the production of the patient's own antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Feb 21, 2026 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Feb 21, 2026 ABN2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Nov 6, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Nov 6, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Nov 6, 2025 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 3, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 31, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 31, 2025 GNSL
SUSPENSION LETTER WRITTEN
Jan 31, 2025 CNSL
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 20, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 20, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jun 20, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 20, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 20, 2024 CRFA
ASSIGNED TO LIE
Jun 20, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 22, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Mar 9, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
Mar 9, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
Mar 9, 2024 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 16, 2024 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 14, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 14, 2023 GNSL
SUSPENSION LETTER WRITTEN
Aug 14, 2023 CNSL
ASSIGNED TO EXAMINER
Jun 29, 2023 DOCK
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 4, 2023 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Dec 1, 2022 GNS2
INQUIRY TO SUSPENSION E-MAILED
Dec 1, 2022 GNSI
SUSPENSION INQUIRY WRITTEN
Dec 1, 2022 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 23, 2022 RCCK
ASSIGNED TO EXAMINER
Oct 26, 2022 DOCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 19, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 19, 2022 GNSL
SUSPENSION LETTER WRITTEN
Apr 19, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 14, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 14, 2022 CRFA
ASSIGNED TO LIE
Apr 13, 2022 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 11, 2022 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 12, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 12, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 12, 2021 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 12, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 12, 2021 GNSL
SUSPENSION LETTER WRITTEN
Apr 12, 2021 CNSL
EXAMINER'S AMENDMENT ENTERED
Apr 12, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 12, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 12, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 12, 2021 CNEA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 18, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 18, 2021 GNSL
SUSPENSION LETTER WRITTEN
Feb 18, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 16, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 16, 2021 CRFA
ASSIGNED TO LIE
Feb 12, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 11, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 18, 2020 GNRN
NON-FINAL ACTION E-MAILED
May 18, 2020 GNRT
NON-FINAL ACTION WRITTEN
May 18, 2020 CNRT
ASSIGNED TO EXAMINER
May 18, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 5, 2020 NWOS
NEW APPLICATION ENTERED
Mar 5, 2020 NWAP